These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37920501)

  • 1. Canada acute coronary syndrome risk score predicts no-/slow-reflow in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Xie E; Li Q; Ye Z; Guo Z; Li Y; Shen N; Yu C; Gao Y; Zheng J
    Heliyon; 2023 Nov; 9(11):e21276. PubMed ID: 37920501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
    Zhang Q; Hu M; Ma S
    J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of the Canada Acute Coronary Syndrome risk score for post-acute myocardial infarction infection.
    Liu Y; Dai Y; Chen J; Huang C; Duan C; Shao S; Chen H; Xue L; Yu D; Chen J; Tan N; He P
    Eur J Intern Med; 2020 Jan; 71():57-61. PubMed ID: 31732453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0.
    Kai T; Oka S; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    Circ J; 2021 Sep; 85(10):1770-1778. PubMed ID: 34305099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nomogram risk prediction model for no-reflow after primary percutaneous coronary intervention based on rapidly accessible patient data among patients with ST-segment elevation myocardial infarction and its relationship with prognosis.
    Liu Y; Ye T; Chen K; Wu G; Xia Y; Wang X; Zong G
    Front Cardiovasc Med; 2022; 9():966299. PubMed ID: 36003914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between kaolin-induced maximum amplitude and slow-flow/no-reflow in ST elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
    Li Q; Xie E; Tu Y; Wu Y; Guo Z; Li P; Li Y; Yu X; Ye Z; Yu C; Gao Y; Jingang Z
    Int J Cardiol; 2022 Dec; 369():13-18. PubMed ID: 35970443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
    Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New CHA
    Zhang QY; Ma SM; Sun JY
    BMC Cardiovasc Disord; 2020 Jul; 20(1):346. PubMed ID: 32711475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Zhao Y; Yang J; Ji Y; Wang S; Wang T; Wang F; Tang J
    Heart Vessels; 2019 Oct; 34(10):1600-1607. PubMed ID: 30993442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aggarwal P; Rekwal L; Sinha SK; Nath RK; Khanra D; Singh AP
    Ann Cardiol Angeiol (Paris); 2021 Jun; 70(3):136-142. PubMed ID: 33962782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification Of Thrombus Burden As An Independent Predictor Of Intra-Procedural No-Reflow In Patients With St-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Revascularization.
    Kumar R; Khan KA; Shah JA; Ammar A; Kumar D; Khowaja S; Sial JA; Kazmi S; Murtaza M; Karim M
    J Ayub Med Coll Abbottabad; 2022; 34(2):288-294. PubMed ID: 35576288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI.
    Acet H; Ertaş F; Akil MA; Bilik MZ; Aydin M; Polat N; Yildiz A
    Turk J Med Sci; 2016 Apr; 46(3):604-13. PubMed ID: 27513233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A score system to predict no-reflow in primary percutaneous coronary intervention: The PIANO Score.
    Dai C; Liu M; Zhou Y; Lu D; Li C; Chang S; Chen Z; Qian J; Ge J
    Eur J Clin Invest; 2022 Feb; 52(2):e13686. PubMed ID: 34596236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of serum uric acid levels with coronary flow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention].
    Wang JW; Chen YD; Wang CH; Zhu XL
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(44):3100-3. PubMed ID: 23328417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Zhang XT; Lin ZR; Zhang L; Zhao ZW; Chen LL
    BMC Cardiovasc Disord; 2022 Mar; 22(1):113. PubMed ID: 35300593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of serum procalcitonin level with the no-reflow phenomenon after a primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction.
    Murat SN; Kurtul A; Celik IE; Duran M; Yarlioglues M; Kilic A; Elcik D
    Coron Artery Dis; 2016 Mar; 27(2):116-21. PubMed ID: 26709984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction.
    Wu G; Wu Z; Xu B; Chen S; Su W; Liu Y; Wu T; Shen Q; Zong G
    J Cardiovasc Transl Res; 2024 Jun; 17(3):657-668. PubMed ID: 37962823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.
    Topuz M; Oz F; Akkus O; Sen O; Topuz AN; Bulut A; Ozbicer S; Okar S; Koc M; Gur M
    Perfusion; 2017 Apr; 32(3):206-213. PubMed ID: 27770057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the predictive value of the modified CADILLAC, GRACE and TIMI risk scores for the risk of short-term death in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention].
    Ji C; Song F; Huang X; Qu X; Qiu N; Zhu J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Mar; 35(3):299-304. PubMed ID: 36916344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
    Kurtul A; Yarlioglues M; Murat SN; Ergun G; Duran M; Kasapkara HA; Demircelik MB; Cetin M; Ocek AH
    Am J Cardiol; 2014 Aug; 114(3):342-7. PubMed ID: 24948493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.